• Sacituzumab govitecan and radiotherapy in metastatic, triple-negative, and BRCA-mutant breast cancer patient with active brain metastases: A case report.
    • di Mauro P, Schivardi G, Pedersini R, Laini L, Esposito A, Amoroso V, Laganà M, Grisanti S, Cosentini D, Berruti A.
    • Front Oncol. 2023 Feb 20;13:1139372. doi: 10.3389/fonc.2023.1139372.
    • Radiotherapy, PARP Inhibition, and Immune-Checkpoint Blockade: A Triad to Overcome the Double-Edged Effects of Each Single Player.
    • Rosado MM, Pioli C.
    • Cancers (Basel). 2023 Feb 8;15(4):1093. doi: 10.3390/cancers15041093.
    • Sociodemographic, Clinical, and Variation Outcomes for Breast Cancer and Breast Cancer-Related Mutations in a Ten-Year Cohort From Neiva, Huila, Colombia.
    • Olaya J, Sanjuan J, Torres-Lopez D, Olaya L, Gutierrez-Vargas M, Olaya G, Olaya JD.
    • Cureus. 2022 Dec 6;14(12):e32257. doi: 10.7759/cureus.32257.
    • BMN673 Is a PARP Inhibitor with Unique Radiosensitizing Properties: Mechanisms and Potential in Radiation Therapy.
    • Soni A, Lin X, Mladenov E, Mladenova V, Stuschke M, Iliakis G.
    • Cancers (Basel). 2022 Nov 16;14(22):5619. doi: 10.3390/cancers14225619.
    • Local treatment in patients with hereditary breast cancer: decision-making process in low-, moderate-, high-penetrance pathogenic germline mutation carriers.
    • Sibilio A, Curcio A, Toesca A, Rossi EMC, Corso G.
    • Curr Opin Oncol. 2022 Nov 1;34(6):614-622. doi: 10.1097/CCO.0000000000000872. Epub 2022 Sep 27.
    • Review
    • Partial Reduction in BRCA1 Gene Dose Modulates DNA Replication Stress Level and Thereby Contributes to Sensitivity or Resistance.
    • Classen S, Rahlf E, Jungwirth J, Albers N, Hebestreit LP, Zielinski A, Poole L, Groth M, Koch P, Liehr T, Kankel S, Cordes N, Petersen C, Rothkamm K, Pospiech H, Borgmann K.
    • Int J Mol Sci. 2022 Nov 1;23(21):13363. doi: 10.3390/ijms232113363.
    • Multigene panel testing might explain the increased risk of secondary malignancies after radiotherapy in Japanese breast cancer patients.
    • Altundag K.
    • Breast Cancer Res Treat. 2022 Nov;196(2):439. doi: 10.1007/s10549-022-06742-w. Epub 2022 Sep 10.

    Related:

    Original research:

    Risk of secondary malignancy after radiotherapy for breast cancer: long-term follow-up of Japanese patients with breast cancer.

    • 18F-FDG Micro PET/CT imaging to evaluate the effect of BRCA1 knockdown on MDA-MB231 breast cancer cell radiosensitivity.
    • Tao W, Wang S, Xu A, Xue Y, Wang H, Xu H.
    • Transl Oncol. 2022 Nov;25:101517. doi: 10.1016/j.tranon.2022.101517. Epub 2022 Aug 17.
    • Nonsurgical Options for Risk Reduction of Contralateral Breast Cancer in BRCA Mutation Carriers With Early-Stage Breast Cancer.
    • Evron E, Ben-David MA, Kaidar-Person O, Corn BW.
    • J Clin Oncol. 2022 Oct 28:JCO2201609. doi: 10.1200/JCO.22.01609. Epub ahead of print.
    • Concurrent Olaparib and Radiotherapy in Patients With Triple-Negative Breast Cancer: The Phase 1 Olaparib and Radiation Therapy for Triple-Negative Breast Cancer Trial.
    • Loap P, Loirat D, Berger F, Rodrigues M, Bazire L, Pierga JY, Vincent-Salomon A, Laki F, Boudali L, Raizonville L, Mosseri V, Jochem A, Eeckhoutte A, Diallo M, Stern MH, Fourquet A, Kirova Y.
    • JAMA Oncol. 2022 Oct 27. doi: 10.1001/jamaoncol.2022.5074. Epub ahead of print.

    Related:

    •• Identifier: NCT03109080: Olaparib & Radiation Therapy for Patients Triple Negative Breast Cancer (TNBC) (RadioPARP). (ClinicalTrials.gov . Accessed 2022 Oct 31.)

    • PTEN Loss Enhances Error-Prone DSB Processing and Tumor Cell Radiosensitivity by Suppressing RAD51 Expression and Homologous Recombination.
    • Pei X, Mladenov E, Soni A, Li F, Stuschke M, Iliakis G.
    • Int J Mol Sci. 2022 Oct 25;23(21):12876. doi: 10.3390/ijms232112876.
    • Comparison of Clinical, Pathological, and Prognostic Features in BRCA Mutant and Wild-Type Male Breast Cancer Patients.
    • Dogan I, Aydin E, Yazici H, Saip P.
    • Eur J Breast Health. 2022 Oct 1;18(4):323-328. doi: 10.4274/ejbh.galenos.2022.2022-5-2.
    • Updates on Management of Hereditary Breast Cancer: New Data on PARP Inhibitors Change Recommendations Regarding the Multidisciplinary Care of Breast Cancer Patients with BRCA Mutations.
    • McGuire KP, Arthur DW, Mamounas EP.
    • Ann Surg Oncol. 2022 Oct;29(11):6504-6507. doi: 10.1245/s10434-022-12048-4. Epub 2022 Jun 18.

    Related:

    Guideline:

    Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline.

    Summary, Review:

    Management of Hereditary Breast Cancer: ASCO, ASTRO, and SSO Guideline.

    Guideline:

    Adjuvant PARP Inhibitors in Patients With High-Risk Early-Stage HER2-Negative Breast Cancer and Germline BRCA Mutations: ASCO Hereditary Breast Cancer Guideline Rapid Recommendation Update.

    • Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D.
    • Graffeo R, Rana HQ, Conforti F, Bonanni B, Cardoso MJ, Paluch-Shimon S, Pagani O, Goldhirsch A, Partridge AH, Lambertini M, Garber JE.
    • Breast. 2022 Oct;65:32-40. doi: 10.1016/j.breast.2022.06.003. Epub 2022 Jun 18.
    • A systematic review exploring the role of modern radiation for the treatment of Hereditary or Familial Breast Cancer.
    • Goel V, Sharma D, Sharma A, Mallick S.
    • Radiother Oncol. 2022 Sep 19;176:59-67. doi: 10.1016/j.radonc.2022.09.007. Epub ahead of print.
    • Review
    • Breast cancer in a teenage girl with BRCA mutation: A case report from a low middle-income country.
    • Vohra LM, Ali D, Hashmi SA, Angez M.
    • Int J Surg Case Rep. 2022 Sep;98:107513. doi: 10.1016/j.ijscr.2022.107513. Epub 2022 Aug 13.
    • Comparison of Outcomes Between BRCA Pathogenic Variant Carriers Undergoing Breast-Conserving Surgery Versus Mastectomy.
    • Shubeck S, Sevilimedu V, Berger E, Robson M, Heerdt AS, Pilewskie ML.
    • Ann Surg Oncol. 2022 Aug;29(8):4706-4713. doi: 10.1245/s10434-022-11756-1. Epub 2022 May 18.

    Related:

    Commentary:

    A Woman Needs to Know She Is a BRCA Carrier Before She Develops Breast Cancer.

    ASO Visual Abstract: Comparison of Outcomes Between BRCA Pathogenic Variant Carriers Undergoing Breast-Conserving Surgery and Those Treated With Mastectomy. (Annals of Surgical Oncology)

    • Satisfaction and Quality of Life of Healthy and Unilateral Diseased BRCA1/2 Pathogenic Variant Carriers after Risk-Reducing Mastectomy and Reconstruction Using the BREAST-Q Questionnaire.
    • Herold N, Hellmich M, Lichtenheldt F, Ataseven B, Hillebrand V, Wappenschmidt B, Schmutzler RK, Rhiem K.
    • Genes (Basel). 2022 Jul 28;13(8):1357. doi: 10.3390/genes13081357.
    • An Overview on Radiation Sensitivity in Hereditary Breast and Ovarian Cancer Syndrome.
    • Gonçalves D, Pires AS, Marques IA, Gomes I, Sousa G, Botelho MF, Abrantes AM.
    • Cancers (Basel). 2022 Jul 2;14(13):3254. doi: 10.3390/cancers14133254.
    • BRCA2-associated Breast Cancer in Transgender Women: Reconstructive Challenges and Literature Review.
    • Cole NA, Copeland-Halperin LR, Shank N, Shankaran V.
    • Plast Reconstr Surg Glob Open. 2022 Apr 22;10(4):e4059. doi: 10.1097/GOX.0000000000004059.
    • Choroidal Metastasis With Secondary Retinal Detachment in a Man With BCRA2-Associated Breast Adenocarcinoma.
    • Sanayei N, Davoudi S, Port A, Chen X.
    • Cureus. 2022 Apr 18;14(4):e24243. doi: 10.7759/cureus.24243.
    • First international workshop of the ATM and cancer risk group (4-5 December 2019).
    • Lesueur F, Easton DF, Renault AL, Tavtigian SV, Bernstein JL, Kote-Jarai Z, Eeles RA, Plaseska-Karanfia D, Feliubadaló L; Spanish ATM working group, Arun B, Herold N, Versmold B, Schmutzler RK; GC-HBOC, Nguyen-Dumont T, Southey MC, Dorling L, Dunning AM, Ghiorzo P, Dalmasso BS, Cavaciuti E, Le Gal D, Roberts NJ, Dominguez-Valentin M, Rookus M, Taylor AMR, Goldstein AM, Goldgar DE; CARRIERS and Ambry Groups, Stoppa-Lyonnet D, Andrieu N.
    • Fam Cancer. 2022 Apr;21(2):211-227. doi: 10.1007/s10689-021-00248-y. Epub 2021 Jun 14.
    • Conference report
    • Combining Carbon-Ion Irradiation and PARP Inhibitor, Olaparib Efficiently Kills BRCA1-Mutated Triple-Negative Breast Cancer Cells.
    • Kawanishi M, Fujita M, Karasawa K.
    • Breast Cancer (Auckl). 2022 Mar 23;16:11782234221080553. doi: 10.1177/11782234221080553.
    • BRCA1 Mutation: An Insidious Enemy with Multiple Facets….
    • Godin P, Duhoux FP, Mazzeo F, Rojas M, Bollue E, François A, Galant C, Coulie J, Coyette M, Lentini A, Deswisen Y, Perlepe V, Fellah L, Leconte I, Berlière M.
    • Case Rep Oncol. 2022 Mar 14;15(1):238-244. doi: 10.1159/000521840.
    • Clinical outcomes and Oncotype DX Breast Recurrence Score® in early-stage BRCA-associated hormone receptor-positive breast cancer.
    • Layman RM, Lin H, Gutierrez Barrera AM, Karuturi MS, Yam C, Arun BK.
    • Cancer Med. 2022 Mar;11(6):1474-1483. doi: 10.1002/cam4.4566. Epub 2022 Feb 6.
    • [A Case of Breast Cancer during Pregnancy Treated with Neoadjuvant Chemotherapy during Pregnancy].
    • Okujima K, Aoki R, Takemoto K, Takaoka M, Kusakabe E, Shidahara T, Noda H, Taguchi K, Nishiyama K, Murakami A, Yamashita M, Kamei Y, Takada Y.
    • Gan To Kagaku Ryoho. 2022 Mar;49(3):289-292. Japanese.
    • Case report. [Article in Japanese]
    • RNA Interference Induces BRCA1 Gene Methylation and Increases the Radiosensitivity of Breast Cancer Cells.
    • Shi Y, Huang R, Zhang Y, Feng Q, Pan X, Wang L.
    • Cancer Biother Radiopharm. 2022 Feb 18. doi: 10.1089/cbr.2021.0346. Epub ahead of print.
    • Breast Irradiation is Well Tolerated in Carriers of a Pathogenic ATM Variant.
    • Zureick AH, Zakalik D, Rangarajan TS, Quinn TJ, Chen PY, Dilworth JT.
    • Int J Radiat Oncol Biol Phys. 2021 Nov 1;111(3S):e227. doi: 10.1016/j.ijrobp.2021.07.780.
    • Heightened Sensitivity of Germline BRCA Mutant Patients Treated With Concurrent or Adjuvant PARP Inhibition and Radiotherapy for Brain Metastases.
    • Santos P, Imber BS, Lapen K, Pike LRG, Moss N, Seidman AD, Beal K.
    • Int J Radiat Oncol Biol Phys. 2021 Nov 1;111(3S):e605. doi: 10.1016/j.ijrobp.2021.07.1614.
    • PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do?
    • Barcellini A, Loap P, Murata K, Villa R, Kirova Y, Okonogi N, Orlandi E.
    • Cancers (Basel). 2021 Oct 27;13(21):5380. doi: 10.3390/cancers13215380.
    • Unique challenges and outcomes of young women with breast cancers from a tertiary care cancer centre in India.
    • Bajpai J, Ventrapati P, Joshi S, Wadasadawala T, Rath S, Pathak R, Nandhana R, Mohanty S, Chougle Q, Engineer M, Abraham N, Ghosh J, Nair N, Gulia S, Popat P, A P, Sheth T, Desai S, Thakur M, Rangrajan V, Parmar V, Sarin R, Gupta S, Badwe RA.
    • Breast. 2021 Oct 6;60:177-184. doi: 10.1016/j.breast.2021.09.008. Epub ahead of print.
    • Outcomes after breast radiotherapy in a diverse patient cohort with a germline BRCA1/2 mutation.
    • Chapman BV, Liu D, Shen Y, Olamigoke OO, Lakomy DS, Barrera AMG, Stecklein SR, Sawakuchi GO, Bright SJ, Bedrosian I, Litton JK, Smith BD, Woodward WA, Perkins GH, Hoffman KE, Stauder MC, Strom EA, Arun BK, Shaitelman SF.
    • Int J Radiat Oncol Biol Phys. 2021 Oct 2:S0360-3016(21)02837-6. doi: 10.1016/j.ijrobp.2021.09.033. Epub ahead of print.
    • Breast radiotherapy-related treatment outcomes in patients with or without germline mutations on multigene panel testing.
    • Chapman BV, Liu D, Shen Y, Olamigoke OO, Lakomy DS, Barrera AMG, Stecklein SR, Sawakuchi GO, Bright SJ, Bedrosian I, Litton JK, Smith BD, Woodward WA, Perkins GH, Hoffman KE, Stauder MC, Strom EA, Arun BK, Shaitelman SF.
    • Int J Radiat Oncol Biol Phys. 2021 Sep 25:S0360-3016(21)02830-3. doi: 10.1016/j.ijrobp.2021.09.026. Epub ahead of print.
    • Harnessing DNA Repair Defects to Augment Immune-Based Therapies in Triple-Negative Breast Cancer.
    • Clark CA, Yang ES.
    • Front Oncol. 2021 Sep 24;11:703802. doi: 10.3389/fonc.2021.703802.
    • Increased Radiosensitivity of Solid Tumors Harboring ATM and BRCA1/2 Mutations.
    • Kim KH, Kim HS, Kim SS, Shim HS, Yang AJ, Lee JJB, Yoon HI, Ahn JB, Chang JS.
    • Cancer Res Treat. 2021 Jun 4. doi: 10.4143/crt.2020.1247. Epub ahead of print.
    • Breast Cancer in Togolese Women: Imaging and Clinicopathological Findings.
    • Darré T, Tchaou M, Djiwa T, Douaguibe B, Bassowa A, Adani-Ifé S, Amavi AK, N'Timon B, Amadou A, Simgban P, N'Bortche BK, Amégbor K, Aboubakari AS, Napo-Koura G.
    • Breast Cancer (Auckl). 2021 May 30;15:11782234211020242. doi: 10.1177/11782234211020242.
    • Risk-Reducing Mastectomy and Reconstruction Following Prophylactic Breast Irradiation: Hope Sustained.
    • Ben David MA, Evron E, Rasco AF, Shai A, Corn BW.
    • Cancers (Basel). 2021 May 30;13(11):2694. doi: 10.3390/cancers13112694.
    • Breast Cancer Adjuvant Radiotherapy in BRCA1/2, TP53, ATM Genes Mutations: Are There Solved Issues?
    • Lazzari G, Buono G, Zannino B, Silvano G.
    • Breast Cancer (Dove Med Press). 2021 May 12;13:299-310. doi: 10.2147/BCTT.S306075.
    • Functional consequences of a rare missense BARD1 c.403G>A germline mutation identified in a triple-negative breast cancer patient.
    • Zheng Y, Li B, Pan D, Cao J, Zhang J, Wang X, Li X, Hou W, Bao D, Ren L, Yang J, Wang S, Qiu Y, Zhou F, Liu Z, Zhu S, Zhang L, Qing T, Wang Y, Yu Y, Wu J, Hu X, Shi L.
    • Breast Cancer Res. 2021 May 1;23(1):53. doi: 10.1186/s13058-021-01428-5.
    • Management of patients with BRCA mutation from the point of view of a breast surgeon.
    • Riis ML.
    • Ann Med Surg (Lond). 2021 Apr 16;65:102311. doi: 10.1016/j.amsu.2021.102311.
    • Management and outcomes of men diagnosed with primary breast cancer.
    • Johnson AE, Coopey SB, Spring LM, Horick NK, Leone JP, Lin NU, Dominici LS, Hughes KS, Jimenez RB.
    • Breast Cancer Res Treat. 2021 Apr 8. doi: 10.1007/s10549-021-06174-y. Epub ahead of print.
    • Comparison of Survival After Breast-Conserving Therapy vs Mastectomy Among Patients With or Without the BRCA1/2 Variant in a Large Series of Unselected Chinese Patients With Breast Cancer.
    • Wan Q, Su L, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y.
    • JAMA Netw Open. 2021 Apr 1;4(4):e216259. doi: 10.1001/jamanetworkopen.2021.6259.

    Related:

    Commentary:

    Mastectomy or Breast-Conserving Therapy for BRCA1/2 Variant Carriers.

    • Clinical practice guidelines for BRCA1 and BRCA2 genetic testing.
    • Pujol P, Barberis M, Beer P, Friedman E, Piulats JM, Capoluongo ED, Garcia Foncillas J, Ray-Coquard I, Penault-Llorca F, Foulkes WD, Turnbull C, Hanson H, Narod S, Arun BK, Aapro MS, Mandel JL, Normanno N, Lambrechts D, Vergote I, Anahory M, Baertschi B, Baudry K, Bignon YJ, Bollet M, Corsini C, Cussenot O, De la Motte Rouge T, Duboys de Labarre M, Duchamp F, Duriez C, Fizazi K, Galibert V, Gladieff L, Gligorov J, Hammel P, Imbert-Bouteille M, Jacot W, Kogut-Kubiak T, Lamy PJ, Nambot S, Neuzillet Y, Olschwang S, Rebillard X, Rey JM, Rideau C, Spano JP, Thomas F, Treilleux I, Vandromme M, Vendrell J, Vintraud M, Zarca D, Hughes KS, Alés Martínez JE.
    • Eur J Cancer. 2021 Feb 9;146:30-47. doi: 10.1016/j.ejca.2020.12.023. Epub ahead of print.
    • Preclinical evaluation of radiation therapy of BRCA1-associated mammary tumors using a mouse model.
    • Cho EJ, Kim JK, Baek HJ, Kim SE, Park EJ, Choi BK, Kim TH, Shin DH, Lim YK, Deng CX, Kim SS.
    • Int J Biol Sci. 2021 Jan 31;17(3):689-701. doi: 10.7150/ijbs.53667.
    • Challenges and Considerations on Risk-Reducing Surgery in BRCA1/2 Patients with Advanced Breast Cancer.
    • Vasconcelos de Matos L, Fernandes L, Louro P, Plácido A, Barros M, Vaz F.
    • Curr Oncol. 2021 Jan 14;28(1):485-490. doi: 10.3390/curroncol28010050.
    • American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline for Management of Hereditary Breast Cancer.
    • Yip CH, Newman LA.
    • JAMA Surg. 2021 Jan 13. doi: 10.1001/jamasurg.2020.6254. Epub ahead of print.
    • Guideline
    • Breast reconstruction in patients with BRCA mutation and breast cancer - our approach.
    • Ventruba Tomáš, Brancíková Dagmar, Ventruba Pavel, Minár Luboš, Felsinger Michal, Vomela Jindrich.
    • Ceska Gynekol. 2021;86(6):374-380. English. doi: 10.48095/cccg2021374.
    • Germline TP53 Testing in Breast Cancers: Why, When and How?
    • Evans DG, Woodward ER, Bajalica-Lagercrantz S, Oliveira C, Frebourg T.
    • Cancers (Basel). 2020 Dec 14;12(12):3762. doi: 10.3390/cancers12123762.
    • Locoregional treatments and ipsilateral breast cancer recurrence rates in BRCA1/2 mutation carriers.
    • Bernstein-Molho R, Laitman Y, Galper S, Jacobson G, Boursi B, Gal-Yam EN, Kaufman B, Friedman E, Kaidar-Person O.
    • Int J Radiat Oncol Biol Phys. 2020 Nov 28:S0360-3016(20)34598-3. doi: 10.1016/j.ijrobp.2020.11.058. Epub ahead of print.
    • Molecular contribution of BRCA1 and BRCA2 to genome instability in breast cancer patients: review of radiosensitivity assays.
    • Sadeghi F, Asgari M, Matloubi M, Ranjbar M, Karkhaneh Yousefi N, Azari T, Zaki-Dizaji M.
    • Biol Proced Online. 2020 Oct 1;22:23. doi: 10.1186/s12575-020-00133-5.
    • Hereditary breast cancer: translation into clinical practice of recent American Society of Clinical Oncology, American Society of Radiation Oncology, and Society of Surgical Oncology recommendations.
    • Corso G, Magnoni F.
    • Eur J Cancer Prev. 2020 Sep 3. doi: 10.1097/CEJ.0000000000000624. Epub ahead of print.
    • Review
    • Male Breast Cancer in Togo: Imaging and Clinicopathological Findings.
    • Darre T, Tchaou M, Djiwa T, Simgban P, Amavi AK, N'Timon B, Amadou A, Bombonne M, Sama B, Amégbor K, Napo-Koura G.
    • Int J Breast Cancer. 2020 Aug 31;2020:3056067. doi: 10.1155/2020/3056067.
    • Evidence for Increased Susceptibility for Breast Cancer from Exposure to Ionizing Radiation Due to Familial Breast Cancer History: Results from the Swedish Hemangioma Cohort.
    • Eidemüller M, Holmberg E, Lundell M, Karlsson P.
    • Am J Epidemiol. 2020 Jul 31:kwaa163. doi: 10.1093/aje/kwaa163. Epub ahead of print.
    • Women with inherited genetic mutations for breast cancer do not always receive treatment according to guidelines.
    • Printz C.
    • Cancer. 2020 Jul 1;126(13):2955. doi: 10.1002/cncr.32999.

    Related:

    Original research:

    Association of Germline Genetic Testing Results With Locoregional and Systemic Therapy in Patients With Breast Cancer.

    • ASTRO Radiation Therapy Summary of the ASCO-ASTRO-SSO Guideline on Management of Hereditary Breast Cancer.
    • Trombetta MG, Dragun A, Mayr NA, Pierce LJ.
    • Pract Radiat Oncol. 2020 Jul-Aug;10(4):235-242. doi: 10.1016/j.prro.2020.04.003. Epub 2020 May 21.

    Related:

    Guideline:

    Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline.

    • Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline.
    • Tung NM, Boughey JC, Pierce LJ, Robson ME, Bedrosian I, Dietz JR, Dragun A, Gelpi JB, Hofstatter EW, Isaacs CJ, Jatoi I, Kennedy E, Litton JK, Mayr NA, Qamar RD, Trombetta MG, Harvey BE, Somerfield MR, Zakalik D.
    • J Clin Oncol. 2020 Jun 20;38(18):2080-2106. doi: 10.1200/JCO.20.00299. Epub 2020 Apr 3.

    Related:

    Summary, Review:

    Management of Hereditary Breast Cancer: ASCO, ASTRO, and SSO Guideline.

    Summary, Review:

    ASTRO Radiation Therapy Summary of the ASCO-ASTRO-SSO Guideline on Management of Hereditary Breast Cancer.

    Commentary, Review:

    Updates on Management of Hereditary Breast Cancer: New Data on PARP Inhibitors Change Recommendations Regarding the Multidisciplinary Care of Breast Cancer Patients with BRCA Mutations.

    • Breast-conserving therapy is safe both within BRCA1/2 mutation carriers and noncarriers with breast cancer in the Chinese population.
    • Huang X, Cai XY, Liu JQ, Hao WW, Zhou YD, Wang X, Xu Y, Chen C, Lin Y, Wang CJ, Song Y, Sun Q.
    • Gland Surg. 2020 Jun;9(3):775-787. doi: 10.21037/gs-20-531.
    • Intraoperative radiotherapy in early breast cancer: observational comparison with whole breast radiotherapy.
    • Oliver Guillén JR, Hernando Almudi E, Molina Osorio G, Ibañez Carreras R, Font Gómez JA, Vicente Gómez I, García Mur C, Casamayor Franco MC.
    • Cir Esp. 2020 May 31:S0009-739X(20)30161-5. English, Spanish. doi: 10.1016/j.ciresp.2020.04.024. Online ahead of print.
    • [Article in English, Spanish]
    • Radiation treatment, ATM, BRCA1/2, and CHEK2*1100delC pathogenic variants, and risk of contralateral breast cancer.
    • Reiner AS, Robson ME, Mellemkjær L, Tischkowitz M, John EM, Lynch CF, Brooks JD, Boice JD, Knight JA, Teraoka SN, Liang X, Woods M, Shen R, Shore RE, Stram DO, Thomas DC, Malone KE, Bernstein L, Riaz N, Woodward W, Powell S, Goldgar D, Concannon P; WECARE Study Collaborative Group, Bernstein JL.
    • J Natl Cancer Inst. 2020 Mar 2. pii: djaa031. doi: 10.1093/jnci/djaa031. [Epub ahead of print]
    • Breast Cancer in Men: A Single Center Experience Over a Period of 22 years.
    • Hoffman A, Ben Ishay O, Horesh N, Shabtai M, Forschmidt E, Rosin D, Gutman M, Ram E.
    • Isr Med Assoc J. 2020 Mar;22(3):160-163.
    • Maximizing Breast Cancer Therapy with Awareness of Potential Treatment-Related Blood Disorders.
    • Kaplan HG, Calip GS, Malmgren JA.
    • Oncologist. 2020 Feb 19. doi: 10.1634/theoncologist.2019-0099. [Epub ahead of print]
    • Radiation Associated Secondary Malignancies in BRCA Mutation Carriers Treated for Breast Cancer.
    • Schlosser S, Rabinovitch R, Shatz Z, Galper S, Shahadi-Dromi I, Finkel S, Jacobson G, Rasco A, Friedman E, Laitman Y, Evron E, Bernstein R, Weiss I, Levy MS, Ben-David MA.
    • Int J Radiat Oncol Biol Phys. 2020 Feb 18. pii: S0360-3016(20)30219-4. doi: 10.1016/j.ijrobp.2020.02.020. [Epub ahead of print]
    • Association of Germline Genetic Testing Results With Locoregional and Systemic Therapy in Patients With Breast Cancer.
    • Kurian AW, Ward KC, Abrahamse P, Hamilton AS, Deapen D, Morrow M, Jagsi R, Katz SJ.
    • JAMA Oncol. 2020 Feb 6:e196400. doi: 10.1001/jamaoncol.2019.6400. [Epub ahead of print]

    Related:

    Press: Breast Cancer Care After Genetic Testing Often Doesn’t Follow Guidelines. (Clinical OMICs)

    Research news:

    Women with inherited genetic mutations for breast cancer do not always receive treatment according to guidelines.

    • Low-Dose and Long-Term Olaparib Treatment Sensitizes MDA-MB-231 and SUM1315 Triple-Negative Breast Cancers Spheroids to Fractioned Radiotherapy.
    • Dubois C, Martin F, Hassel C, Magnier F, Daumar P, Aubel C, Guerder S, Mounetou E, Penault-Lorca F, Bamdad M.
    • J Clin Med. 2019 Dec 26;9(1). pii: E64. doi: 10.3390/jcm9010064.
    • Radiotherapy-induced malignancies in breast cancer patients with TP53 pathogenic germline variants (Li-Fraumeni syndrome).
    • Petry V, Bonadio RC, Cagnacci AQC, Senna LAL, Campos RDNG, Cotti GC, Hoff PM, Fragoso MCBV, Estevez-Diz MDP.
    • Fam Cancer. 2019 Nov 20. doi: 10.1007/s10689-019-00153-5. [Epub ahead of print]
    • Prophylactic breast irradiation reduces background parenchymal enhancement (BPE) on MRI: A secondary analysis.
    • Ben-David MA, Corn BW, Evron E, Goldberg H, Pfeffer RM, Abdah-Bortnyak R, Matceyevsky D, Weinstein Y, Golan O, Sklair-Levy M.
    • Breast. 2019 Nov 6;49:70-73. doi: 10.1016/j.breast.2019.10.011. [Epub ahead of print]
    • Invasive bilateral breast cancer and high grade serous ovarian cancer with BRCA1-germline mutation and brainstem metastasis under PARP inhibitors.
    • Zahari MM, Chiorean AR, Duma MM, Ungureanu A, Kacso G.
    • Arch Clin Cases. 2021 [2019?] Oct 27;6(3):69-75. doi: 10.22551/2019.24.0603.10156.
    • Synergistic Effect of a HER2 Targeted Thorium-227 Conjugate in Combination with Olaparib in a BRCA2 Deficient Xenograft Model.
    • Wickstroem K, Karlsson J, Ellingsen C, Cruciani V, Kristian A, Hagemann UB, Bjerke RM, Ryan OB, Linden L, Mumberg D, Brands M, Cuthbertson A.
    • Pharmaceuticals (Basel). 2019 Oct 15;12(4). pii: E155. doi: 10.3390/ph12040155.
    • Function and mechanism of combined PARP-1 and BRCA genes in regulating the radiosensitivity of breast cancer cells.
    • Zhao W, Hu H, Mo Q, Guan Y, Li Y, Du Y, Li L.
    • Int J Clin Exp Pathol. 2019 Oct 1;12(10):3915-3920. eCollection 2019.
    • Association of a Pathway-Specific Genetic Risk Score With Risk of Radiation-Associated Contralateral Breast Cancer.
    • Watt GP, Reiner AS, Smith SA, Stram DO, Capanu M, Malone KE, Lynch CF, John EM, Knight JA, Mellemkjær L, Bernstein L, Brooks JD, Woods M, Liang X, Haile RW, Riaz N, Conti DV, Robson M, Duggan D, Boice JD Jr, Shore RE, Tischkowitz M, Orlow I, Thomas DC, Concannon P, Bernstein JL.
    • JAMA Netw Open. 2019 Sep 4;2(9):e1912259. doi: 10.1001/jamanetworkopen.2019.12259.
    • Participation in a Novel Trial Assessing Prophylactic Breast Irradiation: The Importance of Input from the Radiation Oncologist.
    • Evron E, Goldberg H, Ben-David MA, Corn BW.
    • Int J Radiat Oncol Biol Phys. 2019 Aug 10. pii: S0360-3016(19)33636-3. doi: 10.1016/j.ijrobp.2019.08.004. [Epub ahead of print]
    • The implications of genetic testing on radiotherapy decisions: a guide for radiation oncologists.
    • Bergom C, West CM, Higginson DS, Abazeed ME, Arun B, Bentzen SM, Bernstein JL, Evans JD, Gerber NK, Kerns SL, Keen J, Litton JK, Reiner AS, Riaz N, Rosenstein BS, Sawakuchi GO, Shaitelman SF, Powell SN, Woodward WA.
    • Int J Radiat Oncol Biol Phys. 2019 Aug 2. pii: S0360-3016(19)33530-8. doi: 10.1016/j.ijrobp.2019.07.026. [Epub ahead of print]
    • Review
    • Prognostic Impact of Breast-Conserving Therapy Versus Mastectomy of BRCA1/2 Mutation Carriers Compared With Noncarriers in a Consecutive Series of Young Breast Cancer Patients.
    • van den Broek AJ, Schmidt MK, van 't Veer LJ, Oldenburg HSA, Rutgers EJ, Russell NS, Smit VTHBM, Voogd AC, Koppert LB, Siesling S, Jobsen JJ, Westenend PJ, van Leeuwen FE, Tollenaar RAEM.
    • Ann Surg. 2019 Aug;270(2):364-372. doi: 10.1097/SLA.0000000000002804.
    • Chromosomal radiosensitivity of triple negative breast cancer patients.
    • Francies FZ, Herd O, Cairns A, Nietz S, Murdoch M, Slabbert J, Claes KB, Vral A, Baeyens A.
    • Int J Radiat Biol. 2019 Jul 26:1-30. doi: 10.1080/09553002.2019.1649502. [Epub ahead of print]
    • Is breast-conserving therapy adequate in BRCA 1/2 mutation carriers? The radiation oncologist's point of view.
    • Vallard A, Magné N, Guy JB, Espenel S, Rancoule C, Diao P, Deutsch E, Rivera S, Chargari C.
    • Br J Radiol. 2019 May;92(1097):20170657. doi: 10.1259/bjr.20170657. Epub 2019 Feb 27.
    • Review

    Related:

    Comment, Letter:

    Implications of the evidence for breast conservation therapy in BRCA-gene mutation carriers.

    • Analysis of Outcomes in Patients With BRCA1/2 Breast Cancer Mutations Treated With Accelerated Partial Breast Irradiation (APBI).
    • Ahmed F, Christos PJ, Singh P, Parashar B, Wernicke AG.
    • Am J Clin Oncol. 2019 Apr 9. doi: 10.1097/COC.0000000000000542. [Epub ahead of print]
    • Contralateral breast irradiation in BRCA carriers: the conundrum of prophylactic versus early treatment.
    • Poortmans PMP, Kaidar-Person O.
    • Ann Oncol. 2019 Mar 1;30(3):348-350. doi: 10.1093/annonc/mdz014.
    • Research news, Editorial
    • Prophylactic irradiation to the contralateral breast for BRCA mutation carriers with early-stage breast cancer.
    • Evron E, Ben-David AM, Goldberg H, Fried G, Kaufman B, Catane R, Pfeffer MR, Geffen DB, Chernobelsky P, Karni T, Abdah-Bortnyak R, Rosengarten O, Matceyevsky D, Inbar M, Kuten A, Corn BW.
    • Ann Oncol. 2019 Mar 1;30(3):412-417. doi: 10.1093/annonc/mdy515.

    Related:

    Editorial:

    Is bilateral radiation an option for BRCA mutation carriers with unilateral breast cancer?

    • Radiosensitivity Is an Acquired Vulnerability of PARPi-Resistant BRCA1-Deficient Tumors.
    • Barazas M, Gasparini A, Huang Y, Küçükosmanoğlu A, Annunziato S, Bouwman P, Sol W, Kersbergen A, Proost N, de Korte-Grimmerink R, van de Ven M, Jonkers J, Borst GR, Rottenberg S.
    • Cancer Res. 2019 Feb 1;79(3):452-460. doi: 10.1158/0008-5472.CAN-18-2077. Epub 2018 Dec 10.
    • Optimise not compromise: The importance of a multidisciplinary breast cancer patient pathway in the era of oncoplastic and reconstructive surgery.
    • Strach MC, Prasanna T, Kirova YM, Alran S, O'Toole S, Beith JM, Poortmans P, McNeil CM, Carroll S.
    • Crit Rev Oncol Hematol. 2019 Feb;134:10-21. doi: 10.1016/j.critrevonc.2018.11.007. Epub 2018 Nov 30.
    • Review
    • Radiation-Induced Colitis in a Pancreatic Cancer Patient With a Germline BRCA2 Mutation: A Case Report.
    • Wolfe AR, Jain R, Pawlik TM, Walker J, Williams TM.
    • Adv Radiat Oncol. 2018 Sep 7;4(1):10-14. doi: 10.1016/j.adro.2018.08.025. eCollection 2019 Jan-Mar.
    • Unusual recurrence of breast cancer in a BRCA-variant patient after fat grafting.
    • Skendelas JP, Lee C, Mangino A, Carson WE 3rd.
    • Clin Case Rep. 2018 Oct 31;6(12):2457-2462. doi: 10.1002/ccr3.1861. eCollection 2018 Dec.
    • Impact of BRCA Mutation Status on Survival of Women With Triple-negative Breast Cancer.
    • Yadav S, Ladkany R, Yadav D, Alhalabi O, Khaddam S, Isaac D, Cardenas PY, Zakalik D.
    • Clin Breast Cancer. 2018 Oct;18(5):e1229-e1235. doi: 10.1016/j.clbc.2017.12.014. Epub 2017 Dec 30.
    • Surgery for BRCA, TP53 and PALB2: a literature review.
    • Song CV, Teo SH, Taib NA, Yip CH.
    • Ecancermedicalscience. 2018 Aug 29;12:863. doi: 10.3332/ecancer.2018.863. eCollection 2018.
    • Indications for Postmastectomy Radiation After Neoadjuvant Chemotherapy in ypN0 and ypN1-3 Axillary Node-Positive Women.
    • Fowble B, Jairam AK, Wang F, Peled A, Alvarado M, Ewing C, Esserman L, Park C, Lazar A.
    • Clin Breast Cancer. 2018 Feb;18(1):e107-e113. doi: 10.1016/j.clbc.2017.07.016. Epub 2017 Aug 1.
    • Enhancing radiosensitisation of BRCA2-proficient and BRCA2-deficient cell lines with hyperthermia and PARP1-i.
    • Oei AL, Ahire VR, van Leeuwen CM, Ten Cate R, Stalpers LJA, Crezee J, Kok HP, Franken NAP.
    • Int J Hyperthermia. 2018 Feb;34(1):39-48. doi: 10.1080/02656736.2017.1324642. Epub 2017 May 19.
    • The PARP-1 inhibitor Olaparib suppresses BRCA1 protein levels, increases apoptosis and causes radiation hypersensitivity in BRCA1+/- lymphoblastoid cells.
    • Bourton EC, Ahorner PA, Plowman PN, Zahir SA, Al-Ali H, Parris CN.
    • J Cancer. 2017 Oct 23;8(19):4048-4056. doi: 10.7150/jca.21338. eCollection 2017.
    • ATM, radiation, and the risk of second primary breast cancer.
    • Bernstein JL; WECARE Study Collaborative Group, Concannon P.
    • Int J Radiat Biol. 2017 Oct;93(10):1121-1127. doi: 10.1080/09553002.2017.1344363. Epub 2017 Jul 27.
    • Severe Late Toxicity After Adjuvant Breast Radiotherapy in a Patient with a Germline Ataxia Telangiectasia Mutated Gene: Future Treatment Decisions.
    • Dosani M, Schrader KA, Nichol A, Sun S, Shenkier T, Lohn Z, Aubertin G, Tyldesley S.
    • Cureus. 2017 Jul 11;9(7):e1458. doi: 10.7759/cureus.1458.
    • A Summary of Recent Oncology Research: Changes to the National Cancer Institute's PDQ Information.
    • [No author given]
    • J Natl Cancer Inst. 2017 Apr 13;109(4). pii: djx080. doi: 10.1093/jnci/djx080. Print 2017 Apr.
    • News

    Related:

    Adjuvant radiotherapy for primary breast cancer in BRCA1 and BRCA2 mutation carriers and risk of contralateral breast cancer with special attention to patients irradiated at younger age.

    • Role of postmastectomy radiotherapy in early-stage (T1-2N0-1M0) triple-negative breast cancer: a systematic review.
    • Chen F, Pu F.
    • Onco Targets Ther. 2017 Apr 6;10:2009-2016. doi: 10.2147/OTT.S123803. eCollection 2017.
    • Analysis of chromosomal radiosensitivity of healthy BRCA2 mutation carriers and non-carriers in BRCA families with the G2 micronucleus assay.
    • Baert A, Depuydt J, Van Maerken T, Poppe B, Malfait F, Van Damme T, De Nobele S, Perletti G, De Leeneer K, Claes KB, Vral A.
    • Oncol Rep. 2017 Mar;37(3):1379-1386. doi: 10.3892/or.2017.5407. Epub 2017 Jan 25.
    • Tumor Cell Recovery from Senescence Induced by Radiation with PARP Inhibition.
    • Gewirtz DA, Alotaibi M, Yakovlev VA, Povirk LF.
    • Radiat Res. 2016 Oct;186(4):327-332. Epub 2016 Sep 2.
    • Patients with a High Polygenic Risk of Breast Cancer do not have An Increased Risk of Radiotherapy Toxicity.
    • Dorling L, Barnett GC, Michailidou K, Coles CE, Burnet NG, Yarnold J, Elliott RM, Dunning AM, Pharoah PD, West CM.
    • Clin Cancer Res. 2016 Mar 15;22(6):1413-20. doi: 10.1158/1078-0432.CCR-15-1080. Epub 2015 Oct 28.
    • Ionizing radiation-induced DNA injury and damage detection in patients with breast cancer.
    • Borrego-Soto G, Ortiz-López R, Rojas-Martínez A.
    • Genet Mol Biol. 2015 Dec;38(4):420-32. doi: 10.1590/S1415-475738420150019. Epub 2015 Nov 24.

    Related:

    Comments on NSGC Discussion Forum Cancer SIG

    Subject: CHEK2 and adjuvant radiation therapy

    • Adjuvant radiotherapy for primary breast cancer in BRCA1 and BRCA2 mutation carriers and risk of contralateral breast cancer with special attention to patients irradiated at younger age.
    • Drooger J, Akdeniz D, Pignol JP, Koppert LB, McCool D, Seynaeve CM, Hooning MJ, Jager A.
    • Breast Cancer Res Treat. 2015 Nov;154(1):171-80.

    Related:

    News:

    A Summary of Recent Oncology Research: Changes to the National Cancer Institute's PDQ Information.

    • BRCA1 Mutation: A Predictive Marker for Radiation Therapy?
    • Kan C, Zhang J.
    • Int J Radiat Oncol Biol Phys. 2015 Oct 1;93(2):281-93. doi: 10.1016/j.ijrobp.2015.05.037.
    • Review
    • BRCA1/2 Mutation-associated Breast Cancer, Wide Local Excision and Radiotherapy or Unilateral Mastectomy: A Systematic Review.
    • Hallam S, Govindarajulu S, Huckett B, Bahl A.
    • Clin Oncol (R Coll Radiol). 2015 Sep;27(9):527-35. doi: 10.1016/j.clon.2015.06.001. Epub 2015 Jun 22.
    • Review

    Related:

    Comment

    Is Breast-conserving Therapy Really a Good Option for BRCA1/2 Mutation Carriers?

    • Effects of Radiation Therapy on Breast Epithelial Cells in BRCA1/2 Mutation Carriers.
    • Chiang HC, Elledge R, Larson P, Jatoi I, Li R, Hu Y.
    • Breast Cancer (Auckl). 2015 Jun 2;9:25-9. doi: 10.4137/BCBCR.S26774. eCollection 2015.
    • Clinical relevance of normal and tumour cell radiosensitivity in BRCA1/BRCA2 mutation carriers: a review.
    • Bernier J, Poortmans P.
    • Breast. 2015 Apr;24(2):100-6. doi: 10.1016/j.breast.2014.12.003. Epub 2014 Dec 31.
    • Review
    • Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
    • Jang NY, Kim DH, Cho BJ, Choi EJ, Lee JS, Wu HG, Chie EK, Kim IA.
    • BMC Cancer. 2015 Mar 3;15:89. doi: 10.1186/s12885-015-1090-7.
    • Radiation therapy in the locoregional treatment of triple-negative breast cancer.
    • Moran MS.
    • Lancet Oncol. 2015 Mar;16(3):e113-e122. doi: 10.1016/S1470-2045(14)71104-0.
    • Review
    • An update on PARP inhibitors for the treatment of cancer.
    • Benafif S, Hall M.
    • Onco Targets Ther. 2015 Feb 26;8:519-28. doi: 10.2147/OTT.S30793. eCollection 2015.
    • Diagnostic and therapeutic ionizing radiation and the risk of a first and second primary breast cancer, with special attention for BRCA1 and BRCA2 mutation carriers: A critical review of the literature.
    • Drooger JC, Hooning MJ, Seynaeve CM, Baaijens MH, Obdeijn IM, Sleijfer S, Jager A.
    • Cancer Treat Rev. 2015 Feb;41(2):187-196. doi: 10.1016/j.ctrv.2014.12.002. Epub 2014 Dec 8.
    • Review
    • The risk factors of toxicity during chemotherapy and radiotherapy in breast cancer patients according to the presence of BRCA gene mutation.
    • Huszno J, Budryk M, Kołosza Z, Nowara E.
    • Contemp Oncol (Pozn). 2015;19(1):72-6. doi: 10.5114/wo.2015.50014. Epub 2015 Mar 26.
    • [PARP inhibitors and radiotherapy: rational and prospects for a clinical use].
    • Pernin V, Mégnin-Chanet F, Pennaneach V, Fourquet A, Kirova Y, Hall J.
    • Cancer Radiother. 2014 Dec;18(8):790-8; quiz 799-802. doi: 10.1016/j.canrad.2014.05.012. Epub 2014 Oct 17.
    • Review, [Article in French]
    • Targeted radiosensitization with PARP1 inhibition: optimization of therapy and identification of biomarkers of response in breast cancer.
    • Feng FY, Speers C, Liu M, Jackson WC, Moon D, Rinkinen J, Wilder-Romans K, Jagsi R, Pierce LJ.
    • Breast Cancer Res Treat. 2014 Aug;147(1):81-94. doi: 10.1007/s10549-014-3085-5. Epub 2014 Aug 8.
    • Active approach for breast cancer genetic counseling during radiotherapy: long-term psychosocial and medical impact.
    • Baars JE, Bleiker EM, van Riel E, Rodenhuis CC, Velthuizen ME, Schlich KJ, Ausems MG.
    • Clin Genet. 2014 Jun;85(6):524-31. doi: 10.1111/cge.12335. Epub 2014 Feb 4.
    • [On the prospects of using the DNA repair inhibitors in radiotherapy of tumors].
    • Gaziev AI.
    • Radiats Biol Radioecol. 2014 May-Jun;54(3):229-40.
    • [Article in Russian]
    • Acute skin toxicity in Korean breast cancer patients carrying BRCA mutations.
    • Park H, Choi DH, Noh JM, Huh SJ, Park W, Nam SJ, Lee JE.
    • Int J Radiat Biol. 2014 Jan;90(1):90-4. doi: 10.3109/09553002.2013.835504. Epub 2013 Sep 19.
    • Management of male breast cancer in the United States: a surveillance, epidemiology and end results analysis.
    • Fields EC, DeWitt P, Fisher CM, Rabinovitch R.
    • Int J Radiat Oncol Biol Phys. 2013 Nov 15;87(4):747-52. doi: 10.1016/j.ijrobp.2013.07.016.
    • The influence of BRCA1/BRCA2 mutations on toxicity related to chemotherapy and radiotherapy in early breast cancer patients.
    • Huszno J, Budryk M, Kołosza Z, Nowara E.
    • Oncology. [2013 Nov;]85(5):278-82. doi: 10.1159/000354834. Epub 2013 Nov 6.
    • Polymorphisms in oxidative stress-related genes and mortality in breast cancer patients--potential differential effects by radiotherapy?
    • Seibold P, Hall P, Schoof N, Nevanlinna H, Heikkinen T, Benner A, Liu J, Schmezer P, Popanda O, Flesch-Janys D, Chang-Claude J.
    • Breast. 2013 Oct;22(5):817-23. doi: 10.1016/j.breast.2013.02.008. Epub 2013 Mar 13.
    • Targeting Aberrant DNA Double-Strand Break Repair in Triple-Negative Breast Cancer with Alpha-Particle Emitter Radiolabeled Anti-EGFR Antibody.
    • Song H, Hedayati M, Hobbs RF, Shao C, Bruchertseifer F, Morgenstern A, Deweese TL, Sgouros G.
    • Mol Cancer Ther. 2013 Oct;12(10):2043-54. doi: 10.1158/1535-7163.MCT-13-0108. Epub 2013 Jul 19.
    • Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: A WECARE Study Report.
    • Bernstein JL, Thomas DC, Shore RE, Robson M, Boice JD Jr, Stovall M, Andersson M, Bernstein L, Malone KE, Reiner AS, Lynch CF, Capanu M, Smith SA, Tellhed L, Teraoka SN, Begg CB, Olsen JH, Mellemkjaer L, Liang X, Diep AT, Borg A, Concannon P, Haile RW; WECARE Study Collaborative.
    • Eur J Cancer. 2013 Sep;49(14):2979-85. doi: 10.1016/j.ejca.2013.04.028. Epub 2013 May 21.
    • Treatment of triple-negative breast cancer using anti-EGFR-directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitor.
    • Al-Ejeh F, Shi W, Miranda M, Simpson PT, Vargas AC, Song S, Wiegmans AP, Swarbrick A, Welm AL, Brown MP, Chenevix-Trench G, Lakhani SR, Khanna KK.
    • J Nucl Med. 2013 Jun;54(6):913-21. doi: 10.2967/jnumed.112.111534. Epub 2013 Apr 5.
    • DNA double-strand break repair as determinant of cellular radiosensitivity to killing and target in radiation therapy.
    • Mladenov E, Magin S, Soni A, Iliakis G.
    • Front Oncol. 2013 May 10;3:113. doi: 10.3389/fonc.2013.00113. eCollection 2013.
    • Variation in telangiectasia predisposing genes is associated with overall radiation toxicity.
    • Tanteles GA, Murray RJ, Mills J, Barwell J, Chakraborti P, Chan S, Cheung KL, Ennis D, Khurshid N, Lambert K, Machhar R, Meisuria M, Osman A, Peat I, Sahota H, Woodings P, Talbot CJ, Symonds RP.
    • Int J Radiat Oncol Biol Phys. 2012 Nov 15;84(4):1031-6. doi: 10.1016/j.ijrobp.2012.02.018. Epub 2012 Jun 6.
    • Association of radiotherapy with preferential depletion of luminal epithelial cells in a BRCA1 mutation carrier.
    • Chiang HC, Nair SJ, Yeh IT, Santillan AA, Hu Y, Elledge R, Li R.
    • Exp Hematol Oncol. 2012 Oct 8;1(1):31. doi: 10.1186/2162-3619-1-31.
    • Options in breast cancer local therapy: who gets what?
    • Jatoi I.
    • World J Surg. 2012 Jul;36(7):1498-502. doi: 10.1007/s00268-012-1530-3.
    • Severe reaction to radiotherapy for breast cancer as the presenting feature of ataxia telangiectasia.
    • Byrd PJ, Srinivasan V, Last JI, Smith A, Biggs P, Carney EF, Exley A, Abson C, Stewart GS, Izatt L, Taylor AM.
    • Br J Cancer. 2012 Jan 17;106(2):262-8. doi: 10.1038/bjc.2011.534. Epub 2011 Dec 6.
    • Is there a role for postmastectomy radiation therapy in ductal carcinoma in situ?
    • Chadha M, Portenoy J, Boolbol SK, Gillego A, Harrison LB.
    • Int J Surg Oncol. 2012;2012:423520. doi: 10.1155/2012/423520. Epub 2012 Jun 13.